200 related articles for article (PubMed ID: 34556523)
1. Mutations in Noncoding
El Ghamrasni S; Quevedo R; Hawley J; Mazrooei P; Hanna Y; Cirlan I; Zhu H; Bruce JP; Oldfield LE; Yang SYC; Guilhamon P; Reimand J; Cescon DW; Done SJ; Lupien M; Pugh TJ
Mol Cancer Res; 2022 Jan; 20(1):102-113. PubMed ID: 34556523
[TBL] [Abstract][Full Text] [Related]
2. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.
Mazrooei P; Kron KJ; Zhu Y; Zhou S; Grillo G; Mehdi T; Ahmed M; Severson TM; Guilhamon P; Armstrong NS; Huang V; Yamaguchi TN; Fraser M; van der Kwast T; Boutros PC; He HH; Bergman AM; Bristow RG; Zwart W; Lupien M
Cancer Cell; 2019 Dec; 36(6):674-689.e6. PubMed ID: 31735626
[TBL] [Abstract][Full Text] [Related]
3. Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer.
D Antonio M; Weghorn D; D Antonio-Chronowska A; Coulet F; Olson KM; DeBoever C; Drees F; Arias A; Alakus H; Richardson AL; Schwab RB; Farley EK; Sunyaev SR; Frazer KA
Nat Commun; 2017 Sep; 8(1):436. PubMed ID: 28874753
[TBL] [Abstract][Full Text] [Related]
4. Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer.
Lowdon RF; Wang T
PLoS One; 2017; 12(3):e0174032. PubMed ID: 28333948
[TBL] [Abstract][Full Text] [Related]
5. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
6. Somatic Mutations Enriched in Cis-Regulatory Elements Affect Genes Involved in Embryonic Development and Immune System Response in Neuroblastoma.
Lasorsa VA; Montella A; Cantalupo S; Tirelli M; de Torres C; Aveic S; Tonini GP; Iolascon A; Capasso M
Cancer Res; 2022 Apr; 82(7):1193-1207. PubMed ID: 35101866
[TBL] [Abstract][Full Text] [Related]
7. Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
Craig JM; Turner TH; Harrell JC; Clevenger CV
Endocrinology; 2021 May; 162(5):. PubMed ID: 33589921
[TBL] [Abstract][Full Text] [Related]
8. Differential Allele-Specific Expression Uncovers Breast Cancer Genes Dysregulated by Cis Noncoding Mutations.
Przytycki PF; Singh M
Cell Syst; 2020 Feb; 10(2):193-203.e4. PubMed ID: 32078798
[TBL] [Abstract][Full Text] [Related]
9. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract][Full Text] [Related]
12. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
13. Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks.
Zhu H; Uusküla-Reimand L; Isaev K; Wadi L; Alizada A; Shuai S; Huang V; Aduluso-Nwaobasi D; Paczkowska M; Abd-Rabbo D; Ocsenas O; Liang M; Thompson JD; Li Y; Ruan L; Krassowski M; Dzneladze I; Simpson JT; Lupien M; Stein LD; Boutros PC; Wilson MD; Reimand J
Mol Cell; 2020 Mar; 77(6):1307-1321.e10. PubMed ID: 31954095
[TBL] [Abstract][Full Text] [Related]
14. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.
Kalyuga M; Gallego-Ortega D; Lee HJ; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Launchbury R; Statham AL; Armstrong N; Alles MC; Young A; Egger A; Au W; Piggin CL; Evans CJ; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JM; Nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ
PLoS Biol; 2012; 10(12):e1001461. PubMed ID: 23300383
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
18. ER regulates an evolutionarily conserved apoptosis pathway.
Liu Z; Chen S
Biochem Biophys Res Commun; 2010 Sep; 400(1):34-8. PubMed ID: 20691160
[TBL] [Abstract][Full Text] [Related]
19. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.
Simeone I; Ceccarelli M
J Transl Med; 2023 Jan; 21(1):55. PubMed ID: 36717859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
